Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 17Cisplatin 11Carboplatin 9Cyclophosphamide 8fludarabine 6Paclitaxel 6Nivolumab 6Bevacizumab 6aldesleukin 5Radiotherapy 5toripalimab 4tisotumab vedotin 4fludarabine phosphate 4Topotecan 4Interleukin-2 4Docetaxel 4Brachytherapy 4spartalizumab 3Ipilimumab 3Fulvestrant 3ferumoxtran-10 2enzalutamide 2durvalumab 2cemiplimab 2bemarituzumab 2balstilimab 2Trastuzumab 2Radiation 2Magnetic Resonance Spectroscopy 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Uterine Cervical Neoplasms × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

NCT00416455 2019-07-23

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
384 enrolled 23 charts
Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡